Inferra AI / Company / AXSM
Axsome Therapeutics, Inc.
AXSM · Health Care
Last earnings Aug 10, 2026
Key results
Revenuequarter
$150.0 million
revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI 2Q 2025 net product
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO launched June 10 th
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
” Financial Highlights • Total net product revenue was $150.0 million for the second quarter of 2025, representing 72% year-over-year growth, and 24% sequential growth compared to the first quarter of 2025.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Total net product revenue for the second quarter of 2024 was $87.2 million.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
1 • SUNOSI net product revenue was $30.0 million for the second quarter of 2025, representing 35% year-over-year growth, and 19% sequential growth compared to the first quarter of 2025.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
SUNOSI net product revenue for the second quarter of 2025 consisted of $28.9 million in net product sales and $1.1 million in royalty revenue associated with SUNOSI sales in out-licensed territories.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
• Total cost of revenue was $13.4 million for the second quarter of 2025.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Total cost of revenue for the comparable period in 2024 was $8.1 million.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
AI analysis
Q2 2025 · reported Aug 4, 2025
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
Guidance · company-stated
No guidance located in the held release
Capital allocation
The Company s primary sources of cash have been proceeds from the sales of AUVELITY, SUNOSI, and SYMBRAVO, the issuance and sale of its common stock in public offerings, and the issuance of debt.
The Company may use a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements if market conditions are favorable or as a result of other strategic considerations to finance its future cash needs.
Company-stated claims
Historical · increased 126% · other
“• New-to-brand prescriptions, representing new AUVELITY patient starts, increased 126% among patients ≥65 years of age during the first eight weeks following the Alzheimer’s disease agitation launch compared to the same period in the prior quarter.”
EX-99 · Aug 10, 2026Event summary
Axsome Therapeutics, Inc. — Earnings release (2025-08-04)
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
The Company s primary sources of cash have been proceeds from the sales of AUVELITY, SUNOSI, and SYMBRAVO, the issuance and sale of its common stock in public offerings, and the issuance of debt.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
The Company may use a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements if market conditions are favorable or as a result of other strategic considerations to finance its future cash needs.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
The Company s financial instruments are cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities, short-term and long-term debt, and current and non-current contingent consideration.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
The carrying value of debt on the Company s balance sheet is estimated to approximate its fair value.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
Debt Issuance Costs Debt issuance costs consist of costs incurred in obtaining long-term financing.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
These costs are classified on the consolidated balance sheet as a direct deduction from the carrying amount of the related debt liability and subsequently amortized as interest expense in the consolidated statement of operations using the effective interest rate method.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
Strategy & priorities
The increase was primarily related to commercialization activities for AUVELITY, including the sales force expansion, and the commercial launch of SYMBRAVO.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
across 10 serious CNS conditions We focus on conditions with high unmet need, strong value creation potential, and clear strategic fit Major depressive disorder Alzheimer’s disease agitation Smoking cessation ADHD Binge eating disorder Neurology Obstructive sleep apnea Migraine Narcolepsy Fibromyalgia Shift work disorder 21M+ ~ People in the U.
SEC original ↗Axsome Therapeutics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025
The Company may use a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements if market conditions are favorable or as a result of other strategic considerations to finance its future cash needs.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
Assets and liabilities that are measured at fair value are reported using a three level fair value hierarchy that prioritizes the inputs used to measure fair value.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
Risks & headwinds
4 Corporate Updates • In May 2025, Axsome announced that it resolved patent litigation with Hetero Labs Ltd.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
SEC original ↗Axsome Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
In addition, these projections, assumptions and estimates are necessarily subject to a high degree of uncertainty and risk.
SEC original ↗Axsome Therapeutics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025
Summary of Significant Accounting Policies Significant Risks and Uncertainties The Company s operations are subject to a number of factors that can affect its operating results and financial condition.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management s judgment.
SEC original ↗Axsome Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026
Earnings deck slides
0 decks with slide viewAxsome Therapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Axsome Therapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Axsome Therapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documents- Q2 2026
- 10-QAXSM
- 8-KAXSM
Aug 10, 2026
- 8-KAXSM
Jul 15, 2026
- Q1 2026
- 8-KAXSM
- 8-KAXSM
- 8-KAXSM
- 10-QAXSM
- 8-KAXSM
- 8-KAXSM
Apr 30, 2026
- 8-KAXSM
- Q4 2025
- 10-KAXSM
Feb 23, 2026
- 8-KAXSM
Feb 23, 2026
- 8-KAXSM
Feb 17, 2026
- 8-KAXSM
Jan 12, 2026
- EX-99AXSM
Jan 12, 2026
- Q3 2025
- 8-KAXSM
Dec 31, 2025
- 10-QAXSM
- 8-KAXSM
- Q2 2025
- 8-KAXSM
Aug 20, 2025
- 10-QAXSM
- 8-KAXSM
- Q1 2025
- 8-KAXSM
Jun 10, 2025
- 8-KAXSM
- 8-KAXSM
- 8-KAXSM
May 27, 2025
- 8-KAXSM
May 13, 2025
- 10-QAXSM
- 8-KAXSM
- 8-KAXSM
- Q4 2024
- 8-KAXSM
Mar 25, 2025
- 8-KAXSM
Earnings releases
10 documentsPresentations
3 documents
Transcripts
0 documentsNo transcripts for Axsome Therapeutics, Inc. are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention Axsome Therapeutics, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“…Exhibit 99.1 Axsome Therapeutics Announces Settlement Resolving All SUNOSI ® (solriamfetol) Patent Litigation NEW YORK, June 3, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutic”
See also the earnings calendar for every tracked company’s next earnings date.